Bausch Health Companies Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Bausch Health Companies de 88.4% y 2% respectivamente, mientras que el BPA crecerá en un 97.2% al año.

Información clave

80.9%

Tasa de crecimiento de los beneficios

97.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	22.8%
Tasa de crecimiento de los ingresos	2.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	30 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Sep 21

Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic

Sep 08

Bausch Health begin offers to exchange debt up to $4B

Aug 31

Bausch Health Stock Down 11%: Now What?

Aug 09

Bausch Health: How To Price The Calamities

Jul 31

Bausch Health: Uncertain, Far From Healthy, But Potentially Lucrative

Jul 18

Previsiones de crecimiento de beneficios e ingresos

NYSE:BHC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	9,933	432	N/A	1,062	5
12/31/2025	9,637	384	1,576	1,470	6
12/31/2024	9,387	336	1,521	1,697	7
12/31/2023	8,757	-592	760	1,032	N/A
9/30/2023	8,542	-963	893	1,117	N/A
6/30/2023	8,350	-186	-665	-428	N/A
3/31/2023	8,150	-357	-773	-511	N/A
12/31/2022	8,124	-225	-996	-728	N/A
9/30/2022	8,127	254	-1,434	-1,179	N/A
6/30/2022	8,192	43	384	648	N/A
3/31/2022	8,325	-407	648	920	N/A
12/31/2021	8,434	-948	1,143	1,426	N/A
9/30/2021	8,451	-1,170	1,512	1,796	N/A
6/30/2021	8,478	-1,287	1,190	1,488	N/A
3/31/2021	8,042	-1,018	988	1,293	N/A
12/31/2020	8,027	-560	802	1,111	N/A
9/30/2020	8,038	-1,923	641	951	N/A
6/30/2020	8,109	-2,043	899	1,210	N/A
3/31/2020	8,597	-1,888	1,046	1,349	N/A
12/31/2019	8,601	-1,788	1,223	1,501	N/A
9/30/2019	8,498	-616	1,329	1,586	N/A
6/30/2019	8,425	-917	1,386	1,593	N/A
3/31/2019	8,401	-1,619	1,241	1,476	N/A
12/31/2018	8,380	-4,148	1,266	1,501	N/A
9/30/2018	8,422	-3,291	1,517	1,760	N/A
6/30/2018	8,505	-1,640	170	1,728	N/A
3/31/2018	8,610	-805	260	1,774	N/A
12/31/2017	8,724	2,404	1,954	2,290	N/A
9/30/2017	8,964	1,376	N/A	2,224	N/A
6/30/2017	9,224	-1,143	N/A	2,304	N/A
3/31/2017	9,411	-1,407	N/A	2,484	N/A
12/31/2016	9,674	-2,409	N/A	2,087	N/A
9/30/2016	10,024	-2,280	N/A	2,172	N/A
6/30/2016	10,332	-1,013	N/A	2,360	N/A
3/31/2016	10,644	-764	N/A	2,323	N/A
12/31/2015	10,442	-292	N/A	2,257	N/A
9/30/2015	9,906	596	N/A	2,476	N/A
6/30/2015	9,175	822	N/A	2,336	N/A
3/31/2015	8,484	1,001	N/A	2,302	N/A
12/31/2014	8,200	881	N/A	2,312	N/A
9/30/2014	8,043	502	N/A	1,759	N/A
6/30/2014	7,529	-746	N/A	1,342	N/A
3/31/2014	6,583	-861	N/A	1,271	N/A
12/31/2013	5,766	-866	N/A	1,042	N/A
9/30/2013	4,626	-1,079	N/A	830	N/A
6/30/2013	3,968	-98	N/A	795	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BHC sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que BHC sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que BHC sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (2% al año) de BHC crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 2% al año) de BHC crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BHC se prevé que sea elevada dentro de 3 años.

Bausch Health Companies Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 10% to US$10.33

Consensus EPS estimates fall from profit to US$0.03 loss

Consensus EPS estimates fall by 89%, revenue upgraded

No longer forecast to breakeven

Consensus EPS estimates fall by 31%

Consensus EPS estimates fall from profit to US$0.49 loss

Recent updates

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Price target increased by 10% to US$10.33

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall from profit to US$0.03 loss

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Consensus EPS estimates fall by 89%, revenue upgraded

New major risk - Negative shareholders equity

No longer forecast to breakeven

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Consensus EPS estimates fall by 31%

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Consensus EPS estimates fall from profit to US$0.49 loss

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Price target increased by 11% to US$9.50

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Executive VP & CFO exercised options to buy US$1.1m worth of stock.

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Consensus EPS estimates increase from loss to US$0.11 profit

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

New major risk - Financial position

Consensus EPS estimates fall by 299%

Price target decreased by 29% to US$8.50

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Consensus EPS estimates upgraded to US$0.18 loss

Price target decreased by 8.9% to US$11.92

Consensus EPS estimates upgraded to US$0.33 loss

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Forecast breakeven date pushed back to 2025

CEO & Director exercised options to buy US$115k worth of stock.

Price target increased by 8.3% to US$13.00

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 24%

Consensus EPS estimates increase by 214%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus EPS estimates increase by 214%

Investor sentiment improved over the past week

Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Investor sentiment deteriorated over the past week

Bausch Health acne lotion Arazlo available in Canada under public drug plans

Bausch Health: Things To Consider Before Investing

Consensus forecasts updated

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Third quarter 2022 earnings: EPS exceeds analyst expectations

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Q3 2022 Earnings Preview